| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | vorinostat:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |